Cantargia (Q1 Review): Shift Towards RAS Combination Strategy - Redeye

Redeye comments on Cantargia's first quarter report 2026. We have revised our valuation and timeline assumptions following Cantargia’s decision to pursue a combination study of nadunolimab with a RAS inhibitor rather than a pivotal programme in combination with gemcitabine/nab-paclitaxel. We believe this will be fertile ground for future licensing deals. This results in a slightly lower new base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1167958/cantargia-q1-review-shift-towards-ras-combination-strategy?utm_source=finwire&utm_medium=RSS